Endoscopic treatment of primary vesicoureteral reflux in children with two different bulking agents, high success and low complication rates: Comparison of Dexell and Vantris.

Autor: Doğan AB; Departamento de Cirugía Pediátrica, Facultad de Medicina, Universidad Erciyes, Kayseri, Turkey. Electronic address: drkarden@gmail.com., Özkan KU; Departamento de Cirugía Pediátrica, Facultad de Medicina, Universidad Erciyes, Kayseri, Turkey., Güler AG; Departamento de Cirugía Pediátrica, Facultad de Medicina, University of Sütçü İmam, Kahramanmaras, Turkey., Karakaya AE; Departamento de Cirugía Pediátrica, Facultad de Medicina, University of Sütçü İmam, Kahramanmaras, Turkey.
Jazyk: English; Spanish; Castilian
Zdroj: Actas urologicas espanolas [Actas Urol Esp (Engl Ed)] 2021 Oct; Vol. 45 (8), pp. 545-551. Date of Electronic Publication: 2021 Sep 12.
DOI: 10.1016/j.acuroe.2021.07.002
Abstrakt: Introduction and Objectives: To compare the results in terms of efficacy and safety of the endoscopic management for vesicoureteral reflux (VUR) in two different standardized primary VUR cohorts treated with Dexell and Vantris.
Patients: 128 refluxing renal units (RRU) in 87 patients with primary VUR (64 females, 23 males). Patients with secondary VUR and severe bladder and bowel dysfunction were excluded. A total of 22 continent children with mild bladder-bowel dysfunction underwent bladder-bowel training before the implantation. All procedures were performed in the presence of sterile urine using a conventional subureteral transurethral injection technique.
Results: There were no statistically significant differences between groups in terms of mean age, sex, RRU side, 99m Tc-DMSA uptake, and reflux grade. The overall resolution rates based on the number of RRUs for up to three endoscopic treatments were 80% (56/70) in Dexell group and 94.8% (55/58) in Vantris group (P = .012). No postoperative recurrences or vesicoureteral junction obstructions were seen in any group.
Conclusions: Dexell and Vantris provided an effective and safe endoscopic VUR treatment in the early and mid-term follow up of children with primary VUR. The effectiveness of these substances, which can produce different mass effects with different particle sizes, in safe VUR resolution, needs further investigations.
(Copyright © 2021 AEU. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: